# Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

> **NCT03721068** · PHASE1 · RECRUITING · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 18 (estimated)

## Conditions studied

- Neuroblastoma
- Osteosarcoma

## Interventions

- **BIOLOGICAL:** iC9.GD2.CAR.IL-15 T-cells
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT03721068
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-02-19
- **Primary completion:** 2030-05-19
- **Final completion:** 2044-06-19
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03721068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03721068, "Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03721068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*